Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$67.4M
1 round on record
Latest round
$67.4M
Series D · Jul 2026 · 2 mo ago
Team
51-200
employees, estimated range
Backers
5
HBM Healthcare Investments, LG Technology Ventures
The money's age
Fresh money
2 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 11, 2024
New executive FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer · businesswire.com
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series D | Jul 2026 | $67.4M | — | morningstar.com |
Backed byfrom the funds' portfolios and accelerator catalogs
HBM Healthcare Investments 
LG Technology Ventures 
Novartis Venture Fund 
OrbiMed 
Pontifax Similar startupsby what they do, their industry and backers
THE CLAUDIN-1 COMPANY Treat cancer and reverse fibrosis We are a clinical-stage biotech company with a mission to treat cancer and reverse…
Sparrow Pharmaceuticals is an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of…
Mustang Bio, Inc. (“Mustang”) is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell…
Together we are transforming the future of Targeted Protein Degradation Our people are at the heart of our success Our commitment to…
TwoStep Therapeutics. Developing tumor-targeted therapies with broad applicability across solid tumors.
Sidewinder Therapeutics is pioneering the next generation of large molecule precision therapeutics. We aim to deliver new life-saving…
News
FORE Biotherapeutics Announces Positive Outcome from First Planned Interim Efficacy Analysis from FORTE Basket Study Evaluating Plixorafenib Monotherapy in Advanced Solid Tumors with BRAF Fusions
Read more
Report
FORE Biotherapeutics Raises $67.4 Million In Series D-2 Extension To Advance Plixorafenib
FORE Biotherapeutics, a registration-stage oncology company focused on targeted cancer therapies, announced the closing of an upsized $67.4 million Series D-2 extension financing, bringing the total raised in the Series D-2 round to $110 million.
Read more
Report
Pro access
Upgrade to see all 20 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Financials
Total raised
$67.4M
Latest round
Series D
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series D | 2026 | $67.4M | Details |